Beyond bacterial defences: the role of lysozyme in cancer

Abstract

Lysozyme (LYZ) is a naturally occurring antimicrobial protein first discovered in the 1920s. As a key component of innate immunity, its antimicrobial effects and immunomodulatory functions in bacterial defence have been extensively characterized. However, emerging evidence since the 1950s has revealed its complex involvement in tumour progression, with conflicting reports of both tumour-suppressive and tumour-promoting effects across different cancer types. A critical knowledge gap remains in understanding the mechanistic basis for this duality, exacerbated by reliance on single-omics approaches and small cohorts in previous studies. This review focuses on mammalian C-type LYZ (referred to as LYZ hereafter unless specified) and integrates multi-omics data (transcriptomics and proteomics) with clinical and mechanistic research to systematically dissect its dual roles in cancer. By analysing cross-cancer heterogeneity through multi-omics perspectives, we emphasize its dual promise as both a prognostic biomarker and an actionable therapeutic target, aiming to provide new insights for precision oncology.

Keywords

biomarker / cancer / lysozyme / LYZ / multi-omics / therapeutic target

References

[1] Fleming A. On a remarkable bacteriolytic element found in tissues and secretions. Proc R Soc London B. 1922; 93(653): 306-317.

[2] Szabo L, Morey R, Palpant NJ, et al. Statistically based splicing detection reveals neural enrichment and tissue-specific induction of circular RNA during human fetal development. Genome Biol. 2015; 16(1): 126.

[3] Fagerberg L, Hallstrom BM, Oksvold P, et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics. 2014; 13(2): 397-406.

[4] Duff MO, Olson S, Wei X, et al. Genome-wide identification of zero nucleotide recursive splicing in drosophila. Nature. 2015; 521(7552): 376-379.

[5] Ragland SA, Criss AK. From bacterial killing to immune modulation: recent insights into the functions of lysozyme. PLoS Pathog. 2017; 13(9):e1006512.

[6] Orthgiess J, Gericke M, Immig K, et al. Neurons exhibit Lyz2 promoter activity in vivo: implications for using LysM-Cre mice in myeloid cell research. Eur J Immunol. 2016; 46(6): 1529-1532.

[7] Guerrero-Juarez CF, Dedhia PH, Jin S, et al. Single-cell analysis reveals fibroblast heterogeneity and myeloid-derived adipocyte progenitors in murine skin wounds. Nat Commun. 2019; 10(1): 650.

[8] Fan C, Song S, Han Y, et al. Targeting lysozyme 2 in endocardium promotes rapid recovery by modulating remote injury signals. Cell Stem Cell. 2025; 32(10): 1563-1576.e11.

[9] Jiang S, Li H, Zhang L, et al. Generic diagramming platform (GDP): a comprehensive database of high-quality biomedical graphics. Nucleic Acids Res. 2025; 53(D1): D1670-D1676.

[10] Wu T, Jiang Q, Wu D, et al. What is new in lysozyme research and its application in food industry? A review. Food Chem. 2019; 274: 698-709.

[11] Xue QG, Schey KL, Volety AK, Chu FL, La Peyre JF. Purification and characterization of lysozyme from plasma of the eastern oyster (Crassostrea virginica). Comp Biochem Physiol B Biochem Mol Biol. 2004; 139(1): 11-25.

[12] Callewaert L, Michiels CW. Lysozymes in the animal kingdom. J Biosci. 2010; 35(1): 127-160.

[13] Muraki M, Goda S, Nagahora H, Harata K. Importance of van der Waals contact between Glu 35 and Trp 109 to the catalytic action of human lysozyme. Protein Sci. 1997; 6(2): 473-476.

[14] Gajda E, Bugla-Ploskonska G. Lysozyme–occurrence in nature, biological properties and possible applications. Postepy Hig Med Dosw (Online). 2014; 68: 1501-1515.

[15] Khorshidian N, Khanniri E, Koushki MR, Sohrabvandi S, Yousefi M. An overview of antimicrobial activity of lysozyme and its functionality in cheese. Front Nutr. 2022; 9:833618.

[16] Wang SW, Wang TY. Study on antibacterial activity and structure of chemically modified lysozyme. Molecules. 2022; 28(1): 95.

[17] Kiristi M, Singh VV, Esteban-Fernandez de Avila B, et al. Lysozyme-based antibacterial nanomotors. ACS Nano. 2015; 9(9): 9252-9259.

[18] Leysen S, Vanderkelen L, Weeks SD, Michiels CW, Strelkov SV. Structural basis of bacterial defense against g-type lysozyme-based innate immunity. Cell Mol Life Sci. 2013; 70(6): 1113-1122.

[19] Ferrari R, Matracia S. Interaction between lysozyme and a phospholipid of neoplastic tissue (oncolipin). Nature. 1961; 192: 1187.

[20] Nash JA, Ballard TN, Weaver TE, Akinbi HT. The peptidoglycan-degrading property of lysozyme is not required for bactericidal activity in vivo. J Immunol. 2006; 177(1): 519-526.

[21] Ibrahim HR, Imazato K, Ono H. Human lysozyme possesses novel antimicrobial peptides within its N-terminal domain that target bacterial respiration. J Agric Food Chem. 2011; 59(18): 10336-10345.

[22] Lonnerdal B. Nutritional and physiologic significance of human milk proteins. Am J Clin Nutr. 2003; 77(6): 1537S-1543S.

[23] Ragland SA, Schaub RE, Hackett KT, Dillard JP, Criss AK. Two lytic transglycosylases in Neisseria gonorrhoeae impart resistance to killing by lysozyme and human neutrophils. Cell Microbiol. 2017; 19(3).

[24] Davis KM, Nakamura S, Weiser JN. Nod2 sensing of lysozyme-digested peptidoglycan promotes macrophage recruitment and clearance of S. pneumoniae colonization in mice. J Clin Invest. 2011; 121(9): 3666-3676.

[25] Masumoto J, Yang K, Varambally S, et al. Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo. J Exp Med. 2006; 203(1): 203-213.

[26] Caruso R, Warner N, Inohara N, Nunez G. NOD1 and NOD2: signaling, host defense, and inflammatory disease. Immunity. 2014; 41(6): 898-908.

[27] Shimada T, Park BG, Wolf AJ, et al. Staphylococcus aureus evades lysozyme-based peptidoglycan digestion that links phagocytosis, inflammasome activation, and IL-1beta secretion. Cell Host Microbe. 2010; 7(1): 38-49.

[28] Rae CS, Geissler A, Adamson PC, Portnoy DA. Mutations of the Listeria monocytogenes peptidoglycan N-deacetylase and O-acetylase result in enhanced lysozyme sensitivity, bacteriolysis, and hyperinduction of innate immune pathways. Infect Immun. 2011; 79(9): 3596-3606.

[29] Wolf AJ, Reyes CN, Liang W, et al. Hexokinase is an innate immune receptor for the detection of bacterial peptidoglycan. Cell. 2016; 166(3): 624-636.

[30] Riber U, Espersen F, Wilkinson BJ, Kharazmi A. Neutrophil chemotactic activity of peptidoglycan. A comparison between Staphylococcus aureus and Staphylococcus epidermidis. APMIS. 1990; 98(10): 881-886.

[31] Short ML, Nickel J, Schmitz A, Renkawitz R. Lysozyme gene expression and regulation. EXS. 1996; 75: 243-257.

[32] Bonifer C, Huber MC, Faust N, Sippel AE. Regulation of the chicken lysozyme locus in transgenic mice. Crit Rev Eukaryot Gene Expr. 1996; 6(2-3): 285-297.

[33] Bonifer C, Jagle U, Huber MC. The chicken lysozyme locus as a paradigm for the complex developmental regulation of eukaryotic gene loci. J Biol Chem. 1997; 272(42): 26075-26078.

[34] Kontaraki J, Chen HH, Riggs A, Bonifer C. Chromatin fine structure profiles for a developmentally regulated gene: reorganization of the lysozyme locus before trans-activator binding and gene expression. Genes Dev. 2000; 14(16): 2106-2122.

[35] Theisen M, Stief A, Sippel AE. The lysozyme enhancer: cell-specific activation of the chicken lysozyme gene by a far-upstream DNA element. EMBO J. 1986; 5(4): 719-724.

[36] Renkawitz R, Schutz G, von der Ahe D, Beato M. Sequences in the promoter region of the chicken lysozyme gene required for steroid regulation and receptor binding. Cell. 1984; 37(2): 503-510.

[37] Goethe R, Loc PV. The far upstream chicken lysozyme enhancer at -6.1 kilobase, by interacting with NF-M, mediates lipopolysaccharide-induced expression of the chicken lysozyme gene in chicken myelomonocytic cells. J Biol Chem. 1994; 269(49): 31302-31309.

[38] Huber MC, Jagle U, Kruger G, Bonifer C. The developmental activation of the chicken lysozyme locus in transgenic mice requires the interaction of a subset of enhancer elements with the promoter. Nucleic Acids Res. 1997; 25(15): 2992-3000.

[39] Kitaguchi T, Kawakami K, Kawahara A. Transcriptional regulation of a myeloid-lineage specific gene lysozyme C during zebrafish myelopoiesis. Mech Dev. 2009; 126(5-6): 314-323.

[40] Moon UY, Bae JH, Kim CH, Kim HJ, Kang JW, Yoon JH. Activation of c-Myb transcription factor is critical for PMA-induced lysozyme expression in airway epithelial cells. J Cell Biochem. 2010; 111(2): 476-487.

[41] Goethe R, Phi-van L. Posttranscriptional lipopolysaccharide regulation of the lysozyme gene at processing of the primary transcript in myelomonocytic HD11 cells. J Immunol. 1998; 160(10): 4970-4978.

[42] Suico MA, Koga T, Shuto T, et al. Sp1 is involved in the transcriptional activation of lysozyme in epithelial cells. Biochem Biophys Res Commun. 2004; 324(4): 1302-1308.

[43] Suico MA, Yoshida H, Seki Y, et al. Myeloid Elf-1-like factor, an ETS transcription factor, up-regulates lysozyme transcription in epithelial cells through interaction with promyelocytic leukemia protein. J Biol Chem. 2004; 279(18): 19091-19098.

[44] Pankratov TA, Gannesen AV, Nikolaev YA. Regulation of lysozyme activity by human hormones. Iran Biomed J. 2023; 27(1): 58-65.

[45] Kobsel N, Ramadori G. Human hepatoma cells synthesize and secrete lysozyme: modulation by cytokines. Hepatology. 1994; 19(5): 1182-1188.

[46] Deng S, Yu K, Zhang B, et al. Effects of over-expression of TLR2 in transgenic goats on pathogen clearance and role of up-regulation of lysozyme secretion and infiltration of inflammatory cells. BMC Vet Res. 2012; 8: 196.

[47] Lubbert M, Henschler R, Kreutz M, Andreesen R, Mertelsmann R, Herrmann F. The human lysozyme gene undergoes stepwise demethylation during phagocyte maturation. Leukemia. 1997; 11(7): 990-997.

[48] Lubbert M, Mertelsmann R, Herrmann F. Cytosine methylation changes during normal hematopoiesis and in acute myeloid leukemia. Leukemia. 1997; 11(Suppl 1): S12-18.

[49] Lefevre P, Lacroix C, Tagoh H, et al. Differentiation-dependent alterations in histone methylation and chromatin architecture at the inducible chicken lysozyme gene. J Biol Chem. 2005; 280(30): 27552-27560.

[50] Myers FA, Lefevre P, Mantouvalou E, et al. Developmental activation of the lysozyme gene in chicken macrophage cells is linked to core histone acetylation at its enhancer elements. Nucleic Acids Res. 2006; 34(14): 4025-4035.

[51] Lefevre P, Witham J, Lacroix CE, Cockerill PN, Bonifer C. The LPS-induced transcriptional upregulation of the chicken lysozyme locus involves CTCF eviction and noncoding RNA transcription. Mol Cell. 2008; 32(1): 129-139.

[52] Akinbi HT, Epaud R, Bhatt H, Weaver TE. Bacterial killing is enhanced by expression of lysozyme in the lungs of transgenic mice. J Immunol. 2000; 165(10): 5760-5766.

[53] Cole AM, Thapa DR, Gabayan V, Liao HI, Liu L, Ganz T. Decreased clearance of Pseudomonas aeruginosa from airways of mice deficient in lysozyme M. J Leukoc Biol. 2005; 78(5): 1081-1085.

[54] Ganz T, Gabayan V, Liao HI, et al. Increased inflammation in lysozyme M-deficient mice in response to Micrococcus luteus and its peptidoglycan. Blood. 2003; 101(6): 2388-2392.

[55] Shimada J, Moon SK, Lee HY, et al. Lysozyme M deficiency leads to an increased susceptibility to Streptococcus pneumoniae-induced otitis media. BMC Infect Dis. 2008; 8: 134.

[56] Markart P, Korfhagen TR, Weaver TE, Akinbi HT. Mouse lysozyme M is important in pulmonary host defense against Klebsiella pneumoniae infection. Am J Respir Crit Care Med. 2004; 169(4): 454-458.

[57] Liu J, Yi C, Ming W, et al. Retinal pigment epithelial cells express antimicrobial peptide lysozyme—a novel mechanism of innate immune defense of the blood-retina barrier. Invest Ophthalmol Vis Sci. 2021; 62(7):21.

[58] Gu Z, Wang L, Dong Q, et al. Aberrant LYZ expression in tumor cells serves as the potential biomarker and target for HCC and promotes tumor progression via csGRP78. Proc Natl Acad Sci U S A. 2023; 120(29):e2215744120.

[59] Mir MA. Lysozyme: a brief review. Postgrad Med J. 1977; 53(619): 257-259.

[60] Perillie PE, Finch SC. Lysozyme in leukemia. Med Clin North Am. 1973; 57(2): 395-407.

[61] Karle H, Hansen NE. Lysozyme and leukemia. Diagnostic, prognostic and pathogenic significance of lysozyme measurements. Ugeskr Laeger. 1974; 136(44): 2451-2455.

[62] Jiang L, Li Y, Wang L, et al. Recent insights into the prognostic and therapeutic applications of lysozymes. Front Pharmacol. 2021; 12:767642.

[63] Baldwin RW. Manipulation of host resistance in cancer therapy. Springer Semin Immunopathol. 1982; 5(2): 113-125.

[64] Chedid L. Muramyl peptides as possible endogenous immunopharmacological mediators. Microbiol Immunol. 1983; 27(9): 723-732.

[65] Collet B, Martin A, Le Garrec Y, Dubray G, Toujas L. Antitumor activity of cell walls from Brucella abortus. J Natl Cancer Inst. 1983; 71(3): 529-534.

[66] Goguel AF, Lespinats G, Nauciel C. Peptidoglycans extracted from gram-positive bacteria: expression of antitumor activity according to peptide structure and route of injection. J Natl Cancer Inst. 1982; 68(4): 657-663.

[67] Sava G, Perissin L, Zorzet S. Antimetastatic action of orally administered lysozyme in mice bearing Lewis lung carcinoma. Clin Exp Metastasis. 1988; 6(3): 245-253.

[68] Fidler IJ, Barnes Z, Fogler WE, Kirsh R, Bugelski P, Poste G. Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators. Cancer Res. 1982; 42(2): 496-501.

[69] Jolles P. A possible physiological function of lysozyme. Biomedicine. 1976; 25(8): 275-276.

[70] Sava G, Ceschia V, Pacor S, Zabucchi G. Observations on the antimetastatic action of lysozyme in mice bearing Lewis lung carcinoma. Anticancer Res. 1991; 11(3): 1109-1113.

[71] Warren JS, Rinehart JJ, Zwilling BS, Neidhart JA. Lysozyme enhancement of tumor cell immunoprotection in a murine fibrosarcoma. Cancer Res. 1981; 41(5): 1642-1645.

[72] LeMarbre P, Rinehart JJ, Kay NE, Vesella R, Jacob HS. Lysozyme enhances monocyte-mediated tumoricidal activity: a potential amplifying mechanism of tumor killing. Blood. 1981; 58(5): 994-999.

[73] Sava G. Reduction of B16 melanoma metastases by oral administration of egg-white lysozyme. Cancer Chemother Pharmacol. 1989; 25(3): 221-222.

[74] Guzel AI, Kasap H, Tuncer I, et al. Suppression of the tumorigenicity of B-16 V melanoma cells via lysozyme gene. Cancer Biother Radiopharm. 2008; 23(5): 603-608.

[75] Mahanta S, Paul S, Srivastava A, Pastor A, Kundu B, Chaudhuri TK. Stable self-assembled nanostructured hen egg white lysozyme exhibits strong anti-proliferative activity against breast cancer cells. Colloids Surf B Biointerfaces. 2015; 130: 237-245.

[76] Cocchietto M, Zorzin L, Veronesi PA, Sava G. Oral poly(ethylene glycol)-conjugated human recombinant lysozyme control of lung metastases in mice. Mol Med Rep. 2008; 1(6): 847-850.

[77] Pacor S, Giacomello E, Bergamo A, et al. Antimetastatic action and lymphocyte activation by the modified lysozyme mPEG-Lyso in mice with MCa mammary carcinoma. Anticancer Res. 1996; 16(5A): 2559-2564.

[78] Pacor S, Gagliardi R, Di Daniel E, Vadori M, Sava G. In vitro down regulation of ICAM-1 and E-cadherin and in vivo reduction of lung metastases of TS/A adenocarcinoma by a lysozyme derivative. Int J Mol Med. 1999; 4(4): 369-375.

[79] Vizoso F, Plaza E, Vazquez J, et al. Lysozyme expression by breast carcinomas, correlation with clinicopathologic parameters, and prognostic significance. Ann Surg Oncol. 2001; 8(8): 667-674.

[80] Sava G, Pacor S, Dasic G, Bergamo A. Lysozyme stimulates lymphocyte response to ConA and IL-2 and potentiates 5-fluorouracil action on advanced carcinomas. Anticancer Res. 1995; 15(5B): 1883-1888.

[81] Zhou H, He X, Huang J, et al. Single-cell sequencing reveals the immune landscape of breast cancer patients with brain metastasis. Thorac Cancer. 2024; 15(9): 702-714.

[82] Behring M, Ye Y, Elkholy A, et al. Immunophenotype-associated gene signature in ductal breast tumors varies by receptor subtype, but the expression of individual signature genes remains consistent. Cancer Med. 2021; 10(16): 5712-5720.

[83] Guo TK, Zhao X, Xie XD, et al. The anti-proliferative effects of recombinant human lysozyme on human gastric cancer cells. J Int Med Res. 2007; 35(3): 353-360.

[84] Khan MI, Dowarha D, Katte R, Chou RH, Filipek A, Yu C. Lysozyme as the anti-proliferative agent to block the interaction between S100A6 and the RAGE V domain. PLoS One. 2019; 14(5):e0216427.

[85] Yu Z, Qiu B, Zhou H, Li L, Niu T. Characterization and application of a lactate and branched chain amino acid metabolism related gene signature in a prognosis risk model for multiple myeloma. Cancer Cell Int. 2023; 23(1): 169.

[86] Yan H, Ding Y, Dai W, et al. Identification and construction of a novel NET-related gene signature for predicting prognosis in multiple myeloma. Clin Exp Med. 2025; 25(1): 147.

[87] Jiang Y, Sun H, Xu H, et al. Immunophenotypic landscape and prognosis-related mRNA signature in diffuse large B cell lymphoma. Front Genet. 2022; 13:872001.

[88] Shi H, Pan Y, Xiang G, et al. A novel NET-related gene signature for predicting DLBCL prognosis. J Transl Med. 2023; 21(1): 630.

[89] Sava G, Benetti A, Ceschia V, Pacor S. Lysozyme and cancer: role of exogenous lysozyme as anticancer agent (review). Anticancer Res. 1989; 9(3): 583-591.

[90] Okushin H, Yamada G, Nagashima H. Immunohistochemical study of fibronectin, lysozyme, and alpha-fetoprotein (AFP) in human hepatocellular carcinoma. Gastroenterol Jpn. 1987; 22(1): 44-54.

[91] Capella C, Cornaggia M, Usellini L, et al. Neoplastic cells containing lysozyme in gastric carcinomas. Pathology. 1984; 16(1): 87-92.

[92] Takahashi T, Akihama T, Yamaguchi A, et al. Lysozyme secreting tumor: a case of gastric cancer associated with myelofibrosis due to disseminated bone marrow metastasis. Jpn J Med. 1987; 26(1): 58-64.

[93] Sarode SC, Sarode GS, Chuodhari S, Patil S. Non-cannibalistic tumor cells of oral squamous cell carcinoma can express phagocytic markers. J Oral Pathol Med. 2017; 46(5): 327-331.

[94] Serra C, Vizoso F, Alonso L, et al. Expression and prognostic significance of lysozyme in male breast cancer. Breast Cancer Res. 2002; 4(6): R16.

[95] Pruzanski W, Platts ME. Serum and urinary proteins, lysozyme (muramidase), and renal dysfunction in mono- and myelomonocytic leukemia. J Clin Invest. 1970; 49(9): 1694-1708.

[96] Hillen JM, Raemaekers JM, Steenbergen EJ, Wetzels JFM, Verhave JC. Progressive kidney failure in chronic myelomonocytic leukaemia: don't forget lysozyme damage. Neth J Med. 2018; 76(9): 407-410.

[97] Robinet-Zimmermann G, Rioux-Leclercq N, Frouget T, Le Naoures C. Lysozyme-induced nephropathy: a rare cause of renal failure in chronic myelomonocytic leukemia. Ann Pathol. 2020; 40(6): 478-482.

[98] Fett JW, Strydom DJ, Lobb RR, et al. Lysozyme: a major secretory product of a human colon carcinoma cell line. Biochemistry. 1985; 24(4): 965-975.

[99] Alderman EM, Lobb RR, Fett JW. Isolation of tumor-secreted products from human carcinoma cells maintained in a defined protein-free medium. Proc Natl Acad Sci U S A. 1985; 82(17): 5771-5775.

[100] Stockl FA, Dolmetsch AM, Saornil MA, Font RL. Orbital granulocytic sarcoma. Br J Ophthalmol. 1997; 81(12): 1084-1088.

[101] Amador-Ortiz C, Hurley MY, Ghahramani GK, et al. Use of classic and novel immunohistochemical markers in the diagnosis of cutaneous myeloid sarcoma. J Cutan Pathol. 2011; 38(12): 945-953.

[102] Luger T, Kokoschka EM, Sagaster P, Micksche M. Serum lysozyme levels in patients with solid tumors. Oncology. 1979; 36(1): 15-18.

[103] Currie GA. Serum lysozyme as a marker of host resistance. II. Patients with malignant melanoma, hypernephroma or breast carcinoma. Br J Cancer. 1976; 33(6): 593-599.

[104] Kraj M, Krzeminska-Lawkowiczowa I, Lawkowicz W, et al. Lysozyme in the serum, urine and peripheral blood leukocytes in patients with immunocytoma. Arch Immunol Ther Exp (Warsz). 1979; 27(6): 875-888.

[105] Moscinski LC. The significance of an elevated serum lysozyme value in acute myelogenous leukemia with eosinophilia. Am J Clin Pathol. 1992; 97(2): 195-201.

[106] Resnitzky P, Shaft D. Distinct lysozyme content in different subtypes of acute myeloid leukaemic cells: an ultrastructural immunogold study. Br J Haematol. 1994; 88(2): 357-363.

[107] Dick W, Dopfer R. Serum lysozyme level in children with acute leukemia and malignant diseases. Padiatr Padol. 1985; 20(1): 25-32.

[108] Shin JH, Park J, Lim J, et al. Metastasis of colon cancer requires Dickkopf-2 to generate cancer cells with Paneth cell properties. Elife. 2024; 13:RP97279.

[109] Tahara E, Ito H, Shimamoto F, Iwamoto T, Nakagami K, Niimoto H. Lysozyme in human gastric carcinoma: a retrospective immunohistochemical study. Histopathology. 1982; 6(4): 409-421.

[110] Han Y, Wang Y, Dong X, et al. TISCH2: expanded datasets and new tools for single-cell transcriptome analyses of the tumor microenvironment. Nucleic Acids Res. 2023; 51(D1): D1425-D1431.

[111] Haghshenas Z, Nazari E, Khalili-Tanha G, Razzaghi Z. Identification of prognostic and diagnostic biomarkers for glioma utilizing immune system gene profiling. Med J Islam Repub Iran. 2025; 39:49.

[112] Osserman EF, Lawlor DP. Serum and urinary lysozyme (muramidase) in monocytic and monomyelocytic leukemia. J Exp Med. 1966; 124(5): 921-952.

[113] Classification of acute leukemia. Ann Intern Med. 1977; 87(6): 740-753.

[114] van der Reijden HJ, van Rhenen DJ, Lansdorp PM, et al. A comparison of surface marker analysis and FAB classification in acute myeloid leukemia. Blood. 1983; 61(3): 443-448.

[115] Lafargue MC, Bobot M, Rennke HG, et al. Chronic myelomonocytic leukemia patients with lysozyme nephropathy and renal infiltration display markers of severe disease. Kidney Int Rep. 2023; 8(12): 2733-2741.

[116] Hennessey TM, Kim MY, Satir BH. Lysozyme acts as a chemorepellent and secretagogue in Paramecium by activating a novel receptor-operated Ca++ conductance. J Membr Biol. 1995; 148(1): 13-25.

[117] Kim MY, Kuruvilla HG, Hennessey TM. Chemosensory adaptation in Paramecium involves changes in both repellent binding and the consequent receptor potentials. Compar Biochem Physiol A Physiol. 1997; 118(3): 589-597.

[118] Kuruvilla HG, Hennessey TM. Purification and characterization of a novel chemorepellent receptor from Tetrahymena thermophila. J Membr Biol. 1998; 162(1): 51-57.

[119] Robinette ED, Gulley KT, Cassity KJ, et al. A comparison of the polycation receptors of Paramecium tetraurelia and Tetrahymena thermophila. J Eukaryot Microbiol. 2008; 55(2): 86-90.

[120] Jiang Y, Sun A, Zhao Y, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature. 2019; 567(7747): 257-261.

[121] Bergamo A, Sava G. Pharmacological modulation of host immunity with hen egg white lysozyme (HEWL)—a review. Molecules. 2023; 28(13): 5027.

[122] Charreire J, Faure A, Bach JF. Studies on B- and T-cell receptors for lysozyme. Immunology. 1975; 29(3): 423-432.

[123] Cecka JM, Stratton JA, Miller A, Sercarz E. Structural aspects of immune recognition of lysozymes. III. T cell specificity restriction and its consequences for antibody specificity. Eur J Immunol. 1976; 6(9): 639-646.

[124] Sette A, Colizzi V, Appella E, Doria G, Adorini L. Analysis of lysozyme-specific immune responses by synthetic peptides. I. Characterization of antibody and T cell-mediated responses to the N-terminal peptide of hen egg-white lysozyme. Eur J Immunol. 1986; 16(1): 1-6.

[125] Varaldo PE, Valisena S, Mingari MC, Satta G. Lysozyme-induced inhibition of the lymphocyte response to mitogenic lectins. Proc Soc Exp Biol Med. 1989; 190(1): 54-62.

[126] Yabe N, Komiya K, Takezono T, Matsui H. Lysozyme as a regulator of interleukin-2-activated lymphocyte proliferation. In Vitro Cell Dev Biol Anim. 1993; 29A(10): 795-806.

[127] Valisena S, Varaldo PE, Ingianni A, Fontana R. Modulatory effects of hen egg-white lysozyme on immune response in mice. New Microbiol. 1996; 19(1): 15-24.

[128] Sava G, Bergamo A, Capozzi I, et al. Stimulation of GALT and activation of mesenteric lymph node lymphocytes by a modified lysozyme in CBA mice with MCa mammary carcinoma. J Exp Ther Oncol. 1996; 1(6): 342-349.

[129] Pacor S, Giacomello E, Bergamo A, Gagliardi R, Cocchietto M, Sava G. Cytofluorimetric analysis of gut-intraepithelial and mesenteric lymph node lymphocytes of tumour bearing mice fed with egg-white lysozyme. Anticancer Res. 1996; 16(1): 145-149.

[130] Cartel F, Cartei G, Ceschia V, Pacor S, Sava G. Recovery of lymphocyte CD4+: CD8+ ratio in patients treated with lysozyme. Drug Investig. 1992; 4(1): 51-57.

[131] Osserman EF, Klockars M, Halper J, Fischel RE. Effects of lysozyme on normal and transformed mammalian cells. Nature. 1973; 243(5406): 331-335.

[132] Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 1999; 8(4): 265-277.

[133] Sava G, Ceschia V, Zabucchi G. Evidence for host-mediated antitumor effects of lysozyme in mice bearing the MCa mammary carcinoma. Eur J Cancer Clin Oncol. 1988; 24(11): 1737-1743.

[134] Chen H, Zhou XH, Li JR, et al. Neutrophils: driving inflammation during the development of hepatocellular carcinoma. Cancer Lett. 2021; 522: 22-31.

[135] Ye YC, Zhao JL, Lu YT, et al. NOTCH signaling via WNT regulates the proliferation of alternative, CCR2-independent tumor-associated macrophages in hepatocellular carcinoma. Cancer Res. 2019; 79(16): 4160-4172.

[136] Li X, Yao W, Yuan Y, et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut. 2017; 66(1): 157-167.

[137] Liu K, He X, Lei XZ, et al. Pathomorphological study on location and distribution of Kupffer cells in hepatocellular carcinoma. World J Gastroenterol. 2003; 9(9): 1946-1949.

[138] Lapis K, Zalatnai A, Timar F, Thorgeirsson UP. Quantitative evaluation of lysozyme- and CD68-positive Kupffer cells in diethylnitrosamine-induced hepatocellular carcinomas in monkeys. Carcinogenesis. 1995; 16(12): 3083-3085.

[139] Namba Y, Hidaka Y, Taki K, Morimoto T. Effect of oral administration of lysozyme or digested bacterial cell walls on immunostimulation in guinea pigs. Infect Immun. 1981; 31(2): 580-583.

[140] Bu HF, Wang X, Zhu YQ, et al. Lysozyme-modified probiotic components protect rats against polymicrobial sepsis: role of macrophages and cathelicidin-related innate immunity. J Immunol. 2006; 177(12): 8767-8776.

[141] Guryanova SV. Regulation of immune homeostasis via muramyl peptides-low molecular weight bioregulators of bacterial origin. Microorganisms. 2022; 10(8): 1526.

[142] Ellis MJ, Gillette M, Carr SA, et al. Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium. Cancer Discov. 2013; 3(10): 1108-1112.

[143] Zhang B, Wang J, Wang X, et al. Proteogenomic characterization of human colon and rectal cancer. Nature. 2014; 513(7518): 382-387.

[144] Cho SY, Hwang H, Kim YH, et al. Refining Classification of cholangiocarcinoma subtypes via proteogenomic integration reveals new therapeutic prospects. Gastroenterology. 2023; 164(7): 1293-1309.

[145] Chen YJ, Roumeliotis TI, Chang YH, et al. Proteogenomics of non-smoking lung cancer in East Asia delineates molecular signatures of pathogenesis and progression. Cell. 2020; 182(1): 226-244.e17.

[146] Xu JY, Zhang C, Wang X, et al. Integrative proteomic characterization of human lung adenocarcinoma. Cell. 2020; 182(1): 245-261.e17.

[147] Zhang Y, Fu F, Zhang Q, et al. Evolutionary proteogenomic landscape from pre-invasive to invasive lung adenocarcinoma. Cell Rep Med. 2024; 5(1):101358.

[148] Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 2012; 13(4): 227-232.

[149] Xing X, Hu E, Ouyang J, et al. Integrated omics landscape of hepatocellular carcinoma suggests proteomic subtypes for precision therapy. Cell Rep Med. 2023; 4(12):101315.

[150] Lehtio J, Arslan T, Siavelis I, et al. Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune evasion mechanisms. Nat Cancer. 2021; 2(11): 1224-1242.

[151] Stewart PA, Welsh EA, Slebos RJC, et al. Proteogenomic landscape of squamous cell lung cancer. Nat Commun. 2019; 10(1): 3578.

[152] Liu Q, Zhang J, Guo C, et al. Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies. Cell. 2024; 187(1): 184-203.e28.

[153] Ge S, Xia X, Ding C, et al. A proteomic landscape of diffuse-type gastric cancer. Nat Commun. 2018; 9(1): 1012.

[154] Ni X, Tan Z, Ding C, et al. A region-resolved mucosa proteome of the human stomach. Nat Commun. 2019; 10(1): 39.

[155] Li C, Sun YD, Yu GY, et al. Integrated omics of metastatic colorectal cancer. Cancer Cell. 2020; 38(5): 734-747.e9.

[156] Hyeon DY, Nam D, Han Y, et al. Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes. Nat Cancer. 2023; 4(2): 290-307.

[157] Li Y, Lih TM, Dhanasekaran SM, et al. Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness. Cancer Cell. 2023; 41(1): 139-163.e17.

[158] McDermott JE, Arshad OA, Petyuk VA, et al. Proteogenomic characterization of ovarian HGSC implicates mitotic kinases, replication stress in observed chromosomal instability. Cell Rep Med. 2020; 1(1):100004.

[159] Hu Y, Pan J, Shah P, et al. Integrated proteomic and glycoproteomic characterization of human high-grade serous ovarian carcinoma. Cell Rep. 2020; 33(3):108276.

[160] Chowdhury S, Kennedy JJ, Ivey RG, et al. Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer. Cell. 2023; 186(16): 3476-3498.e35.

[161] Sinha A, Huang V, Livingstone J, et al. The proteogenomic landscape of curable prostate cancer. Cancer Cell. 2019; 35(3): 414-427.e6.

[162] Zhang F, Zhang Q, Zhu J, et al. Integrated proteogenomic characterization across major histological types of pituitary neuroendocrine tumors. Cell Res. 2022; 32(12): 1047-1067.

[163] Krug K, Jaehnig EJ, Satpathy S, et al. Proteogenomic landscape of breast cancer tumorigenesis and targeted therapy. Cell. 2020; 183(5): 1436-1456.e31.

[164] Jayavelu AK, Wolf S, Buettner F, et al. The proteogenomic subtypes of acute myeloid leukemia. Cancer Cell. 2022; 40(3): 301-317.e12.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.